idarubicin has been researched along with incb-018424 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
2 other study(ies) available for idarubicin and incb-018424
| Article | Year |
|---|---|
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |